Exact Sciences - Oncotype DX GPS Prostate Cancer Business
Exact Sciences (now part of Abbott) sells FDA-approved and laboratory-developed cancer diagnostic tests — including Cologuard stool DNA screening, Oncotype DX genomic tests for breast/colon/prostate, Oncodetect MRD, and Cancerguard MCED — to providers, health systems, and payers via reimbursed laboratory services.
- Company typePublic
- Founded1995
- HeadquartersMadison, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Exact Sciences - Oncotype DX GPS Prostate Cancer Business does
Exact Sciences Corporation, now operating as part of Abbott following an acquisition announced November 20, 2025, is a publicly traded (formerly NASDAQ: EXAS) cancer diagnostics company headquartered at 5505 Endeavor Lane in Madison, Wisconsin. The company sells a portfolio of laboratory-developed and FDA-approved diagnostic tests spanning the full cancer care continuum: Cologuard and Cologuard Plus stool DNA tests for colorectal cancer screening, the Cancerguard multi-cancer early detection (MCED) blood test launched in September 2025, Oncotype DX genomic tests for breast, colon, and prostate cancer (the GPS prostate test being the focus of this analysis), the Oncodetect molecular residual disease (MRD) test, the OncoExTra therapy selection test, Oncoguard Liver for hepatocellular carcinoma surveillance, and the Riskguard hereditary cancer test. Core technology rests on multi-target stool DNA analysis with methylation and mutation biomarkers, circulating tumor DNA (ctDNA) for MRD, DNA methylation plus protein biomarker panels for MCED, and tumor tissue genomic profiling for treatment guidance, all processed in CLIA-certified laboratories in Madison, San Diego, and Redwood City.
The company generates revenue through per-test laboratory service fees reimbursed primarily by Medicare, Medicare Advantage, and commercial insurance under established coverage determinations. Distribution is sales-led via an enterprise field sales force that targets healthcare providers, health systems, and payer organizations; the ExactNexus digital platform connects ordering workflows across providers, payers, and patients. End customers include adults 45+ eligible for routine cancer screening, oncology and urology specialists using genomic recurrence scores for chemotherapy and treatment decisions, health systems running population screening programs, and payers covering Cologuard on a three-year cadence. Strategic assets include 60+ granted US patents covering Cologuard chemistry, FDA approvals on the screening franchise, peer-reviewed clinical evidence from the DeeP-C and BLUE-C pivotal trials published in the New England Journal of Medicine, co-development relationships with Mayo Clinic and Johns Hopkins, and a US/global commercial footprint spanning the Americas, Europe, EMEA, and Asia Pacific.
Exact Sciences - Oncotype DX GPS Prostate Cancer Business firmographics
Firmographics- Name
- Exact Sciences - Oncotype DX GPS Prostate Cancer Business
- Legal name
- Exact Sciences Corporation
- Website
- https://exactsciences.com
- Company type
- Public
- Founded year
- 1995
- Operating status
- Acquired
- Headcount range
- 5,001–10,000 employees
- Short description
- Exact Sciences (now part of Abbott) sells FDA-approved and laboratory-developed cancer diagnostic tests — including Cologuard stool DNA screening, Oncotype DX genomic tests for breast/colon/prostate, Oncodetect MRD, and Cancerguard MCED — to providers, health systems, and payers via reimbursed laboratory services.
- Ownership category
- akta.pro rank
Exact Sciences - Oncotype DX GPS Prostate Cancer Business industry classification
Industry- Product category
- Cancer Diagnostics and Precision Oncology Testing
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)
Keywords
Where Exact Sciences - Oncotype DX GPS Prostate Cancer Business is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Exact Sciences - Oncotype DX GPS Prostate Cancer Business business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Laboratory Testing Services: Exact Sciences generates revenue through laboratory testing services performed at their CLIA-certified facilities. Tests are ordered by healthcare providers and processed in company labs with results delivered to physicians.
- Cancer Screening Tests: Revenue from Cologuard and Cologuard Plus stool-based colorectal cancer screening tests, and Cancerguard multi-cancer early detection blood test.
- Precision Oncology Tests: Oncotype DX tests (Breast Recurrence Score, Breast DCIS Score, Colon Recurrence Score), Oncodetect MRD test, OncoExTra therapy selection test, and Riskguard hereditary cancer test generate revenue through laboratory service fees.
- Payer Reimbursement: Tests are covered by Medicare, Medicare Advantage, and commercial insurance. Medicare coverage established for Cologuard, Oncotype DX tests, and Oncodetect in colorectal cancer. Patient Assistance Program supports access for uninsured/underinsured.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Cologuard and Cologuard Plus - Medicare and commercial insurance covered |
| Transaction based/ take rate | Pay-as-you-go | Oncotype DX Tests - Insurance covered |
| Other | Pay-as-you-go | Patient Assistance Program |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Exact Sciences - Oncotype DX GPS Prostate Cancer Business product offering
Product offeringCore offering
Exact Sciences sells a portfolio of FDA-approved genomic and molecular cancer diagnostic tests, with the Oncotype DX GPS (Genomic Prostate Score) test providing a genomic recurrence and aggressiveness score from prostate tumor tissue to help urologists and patients decide between active surveillance and immediate treatment. The portfolio is rounded out by Oncotype DX Breast Recurrence Score and Colon Recurrence Score treatment-guidance tests, Cologuard and Cologuard Plus non-invasive colorectal cancer screening, Cancerguard multi-cancer early detection, Oncodetect ctDNA-based MRD monitoring, OncoExTra therapy selection, Oncoguard Liver, and Riskguard hereditary cancer testing, all processed at CLIA-certified Exact Sciences laboratories.
Differentiator
Problem solved
Functional benefit
Brands
- Cancerguard: Multi-cancer early detection blood test that helps detect 50+ cancer types
- Cologuard
- Cologuard Plus
- Oncotype DX
- Oncodetect
- OncoExTra
- Oncoguard Liver
- Riskguard
- Exact Oncology
- ExactNexus
Products and services
- Oncotype DX GPS (Genomic Prostate Score)
Quantifiable outcome
- Cologuard detected 92% of colorectal cancers vs 74% for FIT; 42% of advanced precancerous lesions vs 24% for FIT
- +4 more outcomes
Companies that use Exact Sciences - Oncotype DX GPS Prostate Cancer Business
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles4 records
Exact Sciences - Oncotype DX GPS Prostate Cancer Business technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Exact Sciences - Oncotype DX GPS Prostate Cancer Business partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and flagship.
- FreenomecoreExclusive license agreement for Freenome's blood-based colorectal cancer screening tests. This expands Exact Sciences' portfolio of CRC screening options and adds blood-based testing capabilities.
- Mayo ClinicflagshipLong-standing collaborative relationship with Mayo Clinic scientists and clinicians in Rochester, Minnesota. Kevin Conroy and Dr. Graham Lidgard of Exact Sciences met with Dr. David Ahlquist of Mayo Clinic in 2009 to discuss a novel approach for colorectal cancer screening. Together they invented Cologuard, the first and only FDA-approved stool DNA colorectal cancer screening test. Also established broad R&D collaboration focused on identifying biomarkers for 15 deadliest cancers.
- Johns Hopkins UniversityflagshipCollaboration stems from acquisition of Thrive Earlier Detection. Thrive's innovative multi-cancer screening technology was pioneered by researchers from Johns Hopkins University School of Medicine including Bert Vogelstein (pioneer in cancer genomics), Dr. Nickolas Papadopoulos (expert in cancer diagnostics), and Kenneth W. Kinzler (expert on molecular analysis of human cancer).
- TGen (City of Hope)coreTGen became part of City of Hope in 2016 to accelerate translating research discoveries into patient cures. City of Hope is an NCI-designated comprehensive cancer center and founding member of the National Comprehensive Cancer Network, making it a national leader in cancer research and treatment.
- HumanacoreExpanded colorectal cancer screening partnership. Cologuard Plus test became available in-network for Humana members August 2025. Partnership provides broader access to next-generation colorectal cancer screening for Humana's patient population.
- National Cancer InstituteflagshipExact Sciences laboratory and OncoExTra test selected by NCI for ComboMATCH clinical trials. This partnership enables advanced solid tumor patients to access comprehensive genomic profiling through the national clinical trial network.
- Flatiron HealthcorePartnership to advance clinical evidence generation for molecular residual disease testing. Collaboration leverages real-world data and clinical evidence to improve cancer care and support evidence-based medicine.
- PGA Tour ChampionscoreCologuard Classic sponsorship extended through 2027. Partnership includes PGA Tour Champions tournament, celebrity golfer participation, and community events to raise colon cancer awareness and promote screening.
- NSABP FoundationcorePartnership with NSABP Foundation and German Breast Group to present results for Oncodetect MRD test in early triple-negative breast cancer at SABCS 2025.
- National Minority Quality ForumcoreCollaboration to improve cancer screening accessibility, including examining cancer incidence in Flint, Michigan and hosting community cancer screening and health fairs.
- Federally Qualified Health CenterscorePartnership with FQHCs focused on underserved populations. Collaborations include creating assistance programs, engaging patients in their preferred language, and understanding health literacy to better meet community needs.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Exact Sciences - Oncotype DX GPS Prostate Cancer Business competitors and assessment
Company assessmentDirect peers
- Myriad Genetics: Direct competitor in prostate cancer genomics with Prolaris test, which provides cell cycle progression score for prostate cancer prognosis. Competes head-to-head with Oncotype DX GPS in the active surveillance and treatment decision-making market.
- Guardant Health: Direct competitor in liquid biopsy and oncology diagnostics with Guardant360 (tumor profiling) and Reveal (MRD). Competes with Exact Sciences' Oncodetect (MRD) and broader precision oncology portfolio across multiple cancer types including prostate.
- Caris Life Sciences: Direct competitor in oncology molecular profiling (Caris Molecular Intelligence) and MRD (Caris Assure). Competes with Exact Sciences' OncoExTra for therapy selection and Oncodetect for MRD monitoring across solid tumors.
- Foundation Medicine (Roche): Direct competitor in comprehensive genomic profiling for therapy selection with FoundationOne CDx. Competes with Exact Sciences' OncoExTra for advanced solid tumor therapy guidance and is used in similar clinical trial settings (e.g., NCI MATCH trials).
- Natera: Direct competitor in oncology MRD testing with Signatera tumor-informed MRD assay. Competes with Exact Sciences' Oncodetect for monitoring cancer recurrence and treatment response, with significant overlap in colorectal and other solid tumor indications.
- MDxHealth: Direct competitor with SelectMDx and ConfirmMDx prostate cancer diagnostics. Operates in the same urological genomics market as Oncotype DX GPS, focused on biopsy decision-making and prostate cancer risk stratification.
- Veracyte: Acquired Decipher Biosciences in 2021, which provides the Decipher genomic classifier for prostate cancer. Directly competes with Oncotype DX GPS in urological genomics, with complementary positioning in genomic prostate testing and active surveillance.
- GRAIL: Direct competitor in multi-cancer early detection with Galleri test. Competes head-to-head with Exact Sciences' Cancerguard MCED test for early cancer screening using blood-based methylation and biomarker approaches.
Emerging players
- Freenome: Emerging competitor in blood-based colorectal cancer screening. Exact Sciences has an exclusive license for Freenome's blood-based CRC screening tests (announced August 2025), making Freenome both a potential partner and a partial competitor in MCED-adjacent markets.
- Tempus AI: Emerging player in precision oncology with xT (tumor profiling) and xR (RNA) assays. Increasing overlap with Exact Sciences' precision oncology portfolio, though still building scale in MRD and hereditary cancer testing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Exact Sciences - Oncotype DX GPS Prostate Cancer Business social profiles
Digital presenceExact Sciences - Oncotype DX GPS Prostate Cancer Business financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exact Sciences - Oncotype DX GPS Prostate Cancer Business leadership team
Management profileNumber of profiles
Profiles3 records
Exact Sciences - Oncotype DX GPS Prostate Cancer Business subsidiaries and ownership
Company hierarchySubsidiaries3 records
Exact Sciences - Oncotype DX GPS Prostate Cancer Business funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exact Sciences - Oncotype DX GPS Prostate Cancer Business M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exact Sciences - Oncotype DX GPS Prostate Cancer Business
What does Exact Sciences - Oncotype DX GPS Prostate Cancer Business do?
Exact Sciences sells a portfolio of FDA-approved genomic and molecular cancer diagnostic tests, with the Oncotype DX GPS (Genomic Prostate Score) test providing a genomic recurrence and aggressiveness score from prostate tumor tissue to help urologists and patients decide between active surveillance and immediate treatment. The portfolio is rounded out by Oncotype DX Breast Recurrence Score and Colon Recurrence Score treatment-guidance tests, Cologuard and Cologuard Plus non-invasive colorectal cancer screening, Cancerguard multi-cancer early detection, Oncodetect ctDNA-based MRD monitoring, OncoExTra therapy selection, Oncoguard Liver, and Riskguard hereditary cancer testing, all processed at CLIA-certified Exact Sciences laboratories.
Is Exact Sciences - Oncotype DX GPS Prostate Cancer Business a public or private company?
Exact Sciences - Oncotype DX GPS Prostate Cancer Business is a public company. It is classified as corporate owned and is currently acquired.
When was Exact Sciences - Oncotype DX GPS Prostate Cancer Business founded?
Exact Sciences - Oncotype DX GPS Prostate Cancer Business was founded in 1995. It employs 5,001 to 10,000 people.
Where is Exact Sciences - Oncotype DX GPS Prostate Cancer Business based?
Exact Sciences - Oncotype DX GPS Prostate Cancer Business is headquartered in Madison, United States, in the North America region.
How does Exact Sciences - Oncotype DX GPS Prostate Cancer Business make money?
Four revenue lines are on record. Laboratory Testing Services are the primary driver. The others are cancer Screening Tests, precision Oncology Tests and payer Reimbursement.
Who are Exact Sciences - Oncotype DX GPS Prostate Cancer Business's main competitors?
Direct peers on record are Myriad Genetics, Guardant Health, Caris Life Sciences, Foundation Medicine (Roche), Natera, MDxHealth, Veracyte and GRAIL. Emerging players are Freenome and Tempus AI.
Does Exact Sciences - Oncotype DX GPS Prostate Cancer Business have an API?
No public API is recorded for Exact Sciences - Oncotype DX GPS Prostate Cancer Business.
What industry is Exact Sciences - Oncotype DX GPS Prostate Cancer Business in?
Exact Sciences - Oncotype DX GPS Prostate Cancer Business's product category is Cancer Diagnostics and Precision Oncology Testing. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 325413 and its SIC code is 2835.